RESEARCH-USE BIOSIMILAR ANTIBODY
Concizumab
Monoclonal antibody · IgG4
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
TARGETTFPI
YMonoclonal antibody
CATALOGSC-BS-656
CATALOG NUMBERSC-BS-656
MOLECULAR WEIGHTApprox. 146.28 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
Concizumab is a recombinant research-use antibody directed against TFPI.